$UTHR News

United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns

UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

United Therapeutics Corporation Q2 2026 Earnings Call Summary

United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress ...

United Therapeutics Q2 Earnings Call Highlights

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat

United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results